2023-03-08 07:48:20 ET
- Galera Therapeutics press release ( NASDAQ: GRTX ): Q4 GAAP EPS of -$0.58 misses by $0.06 .
- As of December 31, 2022, Galera had cash, cash equivalents and short-term investments of $31.6 million.
- Galera expects that its existing cash, cash equivalents and short-term investments, together with the net proceeds from its February 2023 registered direct offering, will enable Galera to fund its operating expenses and capital expenditure requirements into the fourth quarter of 2023.
For further details see:
Galera Therapeutics GAAP EPS of -$0.58 misses by $0.06